Prime Medicine annual r&d spending
2020
2021
2022
2023
2024
2025
Prime Medicine R&D Spending Growth & History (PRME)
Prime Medicine's r&d spending was $160.6M for fiscal 2025.
View full Prime Medicine company overviewPrime Medicine annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $160.6M | $5.3M | +3.44% |
| 2024 | 2024-12-31 | $155.3M | $7.4M | +4.99% |
| 2023 | 2023-12-31 | $147.9M | $61.2M | +70.54% |
| 2022 | 2022-12-31 | $86.7M | $16.2M | +22.93% |
| 2021 | 2021-12-31 | $70.5M | $67.6M | +2267.45% |
| 2020 | 2020-12-31 | $3.0M | — | — |
Prime Medicine quarterly r&d spending
Q3.21
Q1.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $33.4M | −$8.0M | −19.28% |
| Q1 2026 | 2026-03-31 | $34.1M | −$6.5M | −15.92% |
| Q4 2025 | 2025-12-31 | $34.7M | $605,000 | +1.77% |
| Q3 2025 | 2025-09-30 | $44.0M | $3.6M | +9.05% |
| Q2 2025 | 2025-06-30 | $41.4M | −$1.7M | −3.94% |
| Q1 2025 | 2025-03-31 | $40.6M | $2.8M | +7.38% |
| Q4 2024 | 2024-12-31 | $34.1M | −$7.4M | −17.74% |
| Q3 2024 | 2024-09-30 | $40.3M | −$627,000 | −1.53% |
| Q2 2024 | 2024-06-30 | $43.1M | $8.5M | +24.49% |
| Q1 2024 | 2024-03-31 | $37.8M | $6.9M | +22.33% |
| Q4 2023 | 2023-12-31 | $41.5M | — | — |
| Q3 2023 | 2023-09-30 | $41.0M | $15.9M | +63.56% |
| Q2 2023 | 2023-06-30 | $34.6M | — | — |
| Q1 2023 | 2023-03-31 | $30.9M | $17.2M | +125.78% |
| Q3 2022 | 2022-09-30 | $25.0M | $17.6M | +238.47% |
| Q1 2022 | 2022-03-31 | $13.7M | — | — |
| Q3 2021 | 2021-09-30 | $7.4M | — | — |
Prime Medicine r&d spending trends
Over the last five fiscal years, Prime Medicine's r&d spending increased from $3.0M to $160.6M, a change of $157.7M. The latest reported quarter, Q2 2026, shows $33.4M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prime Medicine source filings ↗